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Abstract:  25 
Brown seaweeds such as Ascophyllum nodosum are a rich source of phlorotannins (oligomers 26 
and polymers of phloroglucinol units), a class of polyphenols that are unique to Phaeophyceae. 27 
At present there is no information on the bioavailability of seaweed polyphenols and limited 28 
evidence on their bioactivity in vivo. Consequently we investigated the gastrointestinal 29 
modifications in vitro of seaweed phlorotannins from Ascophyllum nodosum and their 30 
bioavailability and effect on inflammatory markers in healthy participants. In vitro, some 31 
phlorotannin oligomers were identified after digestion and colonic fermentation. In addition 7 32 
metabolites corresponding to in vitro absorbed metabolites were identified. Urine and plasma 33 
samples contained a variety of metabolites attributed to both un-conjugated and conjugated 34 
metabolites (glucuronides and/or sulfates). In both urine and plasma, the majority of the 35 
metabolites were found in samples collected at late time points (6-24 h), suggesting colonic 36 
metabolism of high molecular weight phlorotannins, with three phlorotannin oligomers 37 
(hydroxytrifuhalol A, 7-hydroxyeckol, C-O-C dimer of phloroglucinol) identified in urine 38 
samples. A significant increase of the cytokine IL-8 was also observed. Our study shows for 39 
the first time that seaweed phlorotannins are metabolized and absorbed, predominantly in the 40 
large intestine, and there is a large inter-individual variation in their metabolic profile. Three 41 
phlorotannin oligomers present in the capsule are excreted in urine. Our study is the first 42 
investigation of the metabolism and bioavailability of seaweed phlorotannins and the role of 43 
colonic biotransformation. In addition IL-8 is a possible target for phlorotannin bioactivity.  44 
  45 
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Introduction: There has been increasing interest in the past few years on the bioactive 46 
compounds present in seaweeds (1; 2; 3). Traditionally, seaweeds are consumed as a food product 47 
in Asian countries and are increasingly used worldwide as ingredients for industrial 48 
applications. In Japan, over 20 species of red, green, and brown algae (seaweed) are included 49 
in meals (4), and daily seaweed consumption per person has remained relatively consistent over 50 
the last 40 years, in the range of 1.50 to 3.65 kg/person/year as reported by a range of studies 51 
(5; 6; 7). Seaweeds are a rich source of polyphenolic compounds (8), and polyphenols extracted 52 
from algae (9; 10) show some similarities to those found in land plants (9; 10; 11). Thus the main 53 
polyphenols found in brown seaweeds are phlorotannins  (12; 13; 14; 15), a type of phenolic 54 
compound  only found in brown seaweeds (16). Brown seaweed phlorotannins are oligomers 55 
and polymers of phloroglucinol units,  and their oligomer and polymer molecular weights can 56 
greatly vary, from 126 Da to 650 kDa (3), comprising up to 15 % of the plant dried weight (11). 57 
It has been reported that the consumption of brown algae is on average 1.342 kg/person/year, 58 
containing 66.652 g of phlorotannins/person/year and 183 mg/person/day (4) (4). Phlorotannins 59 
are classified according to the type of linkages between phloroglucinol units into four main 60 
groups: eckols (with dibenzodioxin linkages), fucols (with a phenyl linkage), fuhalols and 61 
phloroethols (with ether linkages), and fucophloroethols (with ether and phenyl linkages) (16). 62 
Phlorotannins are being increasingly investigated for their vast array of bioactivities (10; 17; 18) 63 
such as antioxidant (19; 20; 21; 22; 23; 24), anti-inflammatory (20; 25; 26), antibacterial (27; 28), anticancer 64 
(29; 30; 31; 32; 33), and antidiabetic (29; 34; 35), showing promising potential to further develop 65 
seaweed-derived products rich in bioactive components with commercial potential for food and 66 
pharma applications (36).  67 
Bioavailability is a critical factor influencing in vivo biological activity of polyphenols and we 68 
have reasonable understanding of the bioavailability of polyphenols from fruits and vegetables, 69 
and some of the mechanisms by which they exert beneficial effects in vivo have been 70 
determined (37).  Their ability to act as effective bioactive molecules in vivo is dependent on the 71 
extent of their biotransformation (24) and conjugation during absorption from the 72 
gastrointestinal (GI) tract, in the liver and finally in cells (37). Consequently, consideration must 73 
be given to the way polyphenols are absorbed and metabolised during gastrointestinal digestion 74 
and colonic fermentation and how this may impact on bioactivity (38). It is noteworthy that there 75 
is no information on the bioavailability of seaweed phlorotannins and this is a limitation to 76 
understanding their bioactivity and mechanism of action in vivo. In the absence of specific data 77 
regarding phlorotannin absorption and bioavailability, it is useful to consider the absorption 78 
and metabolism of other polyphenols as a guide (37).  In general, after ingestion of a polyphenol-79 
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rich diet, their protective effects  in vivo are determined by measuring a range of suitable 80 
biomarkers, and correlate with the absorption of polyphenols from the gut and their 81 
circulation/excretion (38). Polyphenols can be extensively conjugated to form glucuronide, 82 
sulphate and methyl group in the gut mucosa and inner tissues (37; 39), and absorption occurrs in 83 
the small intestine (37).  Polyphenols unabsorbed in the upper gastrointestinal tract or re-84 
excreted in the bile, are extensively metabolised by colonic microflora into a wide range of low 85 
molecular weight phenolic acids (40). The aim of this study was to elucidate the gastrointestinal 86 
modifications of seaweed phlorotannins, and the effects on their metabolism and 87 
bioavailability. A food grade seaweed polyphenol extract (SPE) rich in phlorotannins (from 88 
the brown seaweed Ascophyllum nodosum) was subjected to in vitro gastrointestinal digestion 89 
and fermentation to examine the gastrointestinal modifications occurring in the upper- and 90 
lower- GI tract. Furthermore, the absorption and metabolism of polyphenols in healthy subjects 91 
was investigated, after oral ingestion of a SPE capsule containing 101.89 mg of polyphenols. 92 
This amount represents an intake lower than the average daily intake of seaweed polyphenols 93 
in the Asian diet, and it is not expected to exert any cytotoxic effect (41). The impact of 94 
absorption and gastrointestinal modifications on phlorotannins anti-inflammatory potential is 95 
explored. 96 
  97 
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Experimental methods 98 
 99 
Seaweed material.  Fresh Ascophyllum nodosum was supplied by The Hebridean Seaweed 100 
Company, Isle of Lewis, Scotland in March 2011. The seaweed biomass was harvested by 101 
hand, cleaned and then shipped refrigerated to the processing facility in France where it was 102 
immediately chopped and frozen. 103 
 104 
Preparation of food-grade SPE and capsule.  A novel SPE from Ascophyllum nodosum was 105 
produced by CEVA (France) using a solvent based extraction system that was specifically 106 
developed for this study and for use with either fresh or frozen Ascophyllum nodosum. The 107 
solvent used was a 60:40 ethanol:water mixture which allowed for the water content of the 108 
seaweed itself. The extraction was carried out over 5 hours using constant stirring and at all 109 
times protected from light. A solvent:seaweed ratio of 3:1 was used. The mixture was filtered 110 
to remove the supernatant and subsequently the alcohol was removed using a rotary evaporator. 111 
A hydrometer was used to check that all the alcohol had been removed. The final extract was 112 
recovered by centrifugation and further filtration before freeze drying. 113 
Approximately half of the produced extract (basic extract) was then fractionated using 114 
tangential flow ultra filtration to produce further extracts of varying molecular weight range 115 
and with varying polyphenol content. A blended SPE was formulated (Table 1) using 175 mg 116 
of basic extract and 50 mg of high molecular weight (HMW) fraction (>10 kDa cut off) for use 117 
in the current study. Maltodextrin (175 mg) was added to the capsule formulation as an 118 
excipient. This was done in order to maximise the polyphenol content (>100 mg per day) but 119 
also to minimise the level of iodine to within accepted regulatory guidelines (< 500 μg per day). 120 
Blending was carried out at the food grade CEVA facilities in France.  400 mg doses of the 121 
SPE Ascophyllum blend were packed into white, opaque, vegetarian capsules by Irish 122 
Seaweeds, Belfast, UK and used for the clinical study. The food grade seaweed capsule was 123 
characterized by NP-HPLC and LC-MS analysis. Phlorotannins were quantified using the 124 
Folin-Ciocalteau Method (42) using phloroglucinol as the standard (8). 125 
 126 
Simulated Gastro-Intestinal Digestion and Fermentation:  The Gastro-Intestinal Digestion 127 
procedure was adapted from Mills et al. (2008) and McDougall et al. (2005). This method 128 
consists of two sequential stages: gastric digestion and small intestinal digestion followed by 129 
dialysis. 10 g of SPE was dissolved in 30 ml acidified water (pH=2) and pepsin (320 U/ml) 130 
was added. Samples were incubated at 37 °C for 2 h on a shaker covered with foil to protected 131 
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from light. 5 ml aliquots (G) were removed. The pH was adjusted to 7.5 by adding few drops 132 
of 6 M NaOH, and pancreatin (4 mg/ml) and bile extracts (25 mg/ml) were added. The samples 133 
were incubated at 37 °C for 2 h on a shaker. 5 ml aliquots (SI) were removed. Samples were 134 
transferred into the dialysis tubing (100-500 Da, cut-off, 1.8 ml/cm, Spectra/Por, Biotech) and 135 
dialysed overnight at 4 °C against water (4 L) to remove low molecular weight digests. 5 ml 136 
aliquots of dialysis solution (D1) were removed. The dialysis fluid was changed and dialysis 137 
continued for additional 2 h. 5 ml aliquots of second dialysis solution (D2) were removed. 138 
Samples (SI+D) were freeze-dried and subjected to colonic fermentation (Batch Culture):  The 139 
method was adapted from Tzounis et al. (2008). Batch-culture fermentation vessels (300 ml; 140 
one vessel per treatment) were autoclaved and filled with 135 ml sterilized basal medium. 141 
Medium was stirred and gassed overnight with O2-free N2. Before addition of SI+D digested 142 
extracts equivalent to 1.5 g of undigested extracts, the temperature inside the vessels was set to 143 
37 °C by a circulating water bath and the pH was controlled at 6.8 by an Electrolab pH 144 
controller, in order to mimic conditions in the distal region of the human large intestine 145 
(anaerobic; 37 °C; pH 6.8). Vessels were inoculated with 15 ml faecal slurry (1:10, w/v) and 146 
batch cultures were run for 24 h 7 ml samples were collected at five time points (0, 2, 4, 8 and 147 
24 h), centrifuged at 13,000 rpm at 4 °C for 10 min and the supernatants were kept. All the 148 
samples collected during the digestion and fermentation procedure were stored at -80 °C until 149 
LC-MS analysis. 150 
 151 
Study design:  This study was conducted according to the guidelines laid down in the 152 
Declaration of Helsinki and all procedures involving human subjects/patients were approved 153 
by the University of Reading Ethics Committee before initiation of the study. Written informed 154 
consent was obtained from all participants. Exclusion criteria for subjects were: smokers, BMI 155 
< 18 or > 30, abnormal liver function and haematology, alcohol intake of > 21 units/wk, 156 
gastrointestinal disease or chronic gastrointestinal disorders, consumption of antibiotics in 157 
previous 3 months before study, females who were pregnant or intending to become pregnant.  158 
Potentially suitable participants underwent a screening process and individuals with blood 159 
pressure > 150/90 mmHg; Hb > 125 g/l for men and > 110 g/l for women; g-glutamyl 160 
transferase > 1·3 mkat/l or cholesterol > 6·5 mmol/l were excluded from the study. In total 24 161 
volunteers were recruited - 12 females (6 aged 18-30 years and 6 aged 30-65 years) and 12 162 
males (6 aged 18-30 years and 6 aged 30-65 years). Participants were asked to follow a low 163 
phenolic diet for 1 day prior to the study day (devoid of tea, coffee, fruit, vegetables, alcoholic 164 
beverages, cocoa, whole- grain and seaweed-containing products). On the study day, the 165 
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subjects were cannulated and a baseline blood sample was taken. Participants were asked to 166 
consume one SPE capsule (400 mg) containing 101.89 mg of polyphenols. Blood samples were 167 
collected at 0, 1, 2, 3, 4, 6, 8 and 24 hours after ingestion of the SPE capsule, and urine samples 168 
were collected at baseline, 0-8 and 8-24 h after the ingestion. During the day, participants were 169 
provided with a lunch and dinner of low phenolic content. The study is registered at 170 
clinicaltrials.gov (study ID: NCT02496806). 171 
 172 
Sample collection and storage: One aliquot of blood was collected in heparin tubes and 173 
cultured immediately (whole blood culture for cytokine analysis).  One aliquot of blood was 174 
collected in EDTA tubes and centrifuged at 3000 rpm for 15 min at 4˚C. The plasma was 175 
separated and 1 mg/ml ascorbic acid was added as preservative. Aliquots were stored at -80 ˚C 176 
until analysis. Total volume of collected urine was recorded and aliquots were stored at -80 ˚C 177 
until analysis. 178 
 179 
Plasma sample processing for metabolite analysis:  Plasma samples were prepared 180 
following a procedure similar to the one described by Ottaviani et al. (43). 10 µl of internal 181 
standard solution (resorcinol 200 µg/ml) were added to 450 µl of plasma, then 50 µl of 1.2 M 182 
acetic acid were added and samples were mixed. Samples were analysed with and without 183 
enzymatic treatment (37 °C, 40 min) in the presence of 1500 IU of β­glucuronidase and 50 IU 184 
of sulfatases from Helix pomatia (Type H-1). 1 ml of 100 % methanol acidified with 0.5 % 185 
acetic acid was added and samples were centrifuged for 15 min at 16,100 x g at 4 °C and 186 
supernatants were collected. This step was repeated 3 times (last time with 50 % methanol 187 
acidified with 0.5 % acetic acid) and the supernatants were dried using a Speedvac. The pellets 188 
were dissolved with 125 µl of mobile phase and transferred to vials for RP-HPLC analysis. 189 
 190 
Urine sample processing for metabolite analysis:  Urine samples were prepared following a 191 
procedure similar to the one described by Ottaviani et al. (43). Briefly, 10 µl of internal standard 192 
solution (resorcinol 200 µg/ml) were added to 250 µl urine. Samples were analysed with and 193 
without enzymatic treatment (37 °C, 40 min), in the presence of 1500 IU of β­glucuronidase 194 
and 50 IU of sulfatases from H. pomatia (Type H-1). 1 ml of 100 % methanol acidified with 195 
0.5 % acetic acid was added, samples were mixed and centrifuged for 15 min at 16.100 g (rcf) 196 
at 4 °C, supernatants were transferred to a new tube and dried on a Speedvac. Dried samples 197 
were re-suspended on 125 µl of mobile phase, completely dissolved, centrifuged and 198 




NP-HPLC analysis:  The phlorotannins in the food-grade SPE used to produce the capsule 201 
were analyzed by normal phase HPLC analysis (8) using an HPLC 1100 series equipped with  202 
LiChrospher Si60-5 column (250 mm × 4.0 mm ID, 5 μm particle size from HICHROM 203 
(LISP60-5-250AF), fitted with a guard column LiChrospher Si60-5 from HICHROM (LISP60-204 
5-10C5). The mobile phase contained A: 82 % dichloromethane + 2 % methanol + 2 % acetic 205 
acid in water and B: 96 % methanol + 2 % acetic acid in water and was pumped through the 206 
column at 1 ml/min. 10 µl of samples were injected and analyzed by the gradient program 207 
which were (min/%B): 0/0, 30/17.6,45/30.7, 50/87.8, 60/87.8, 80/0, 105/0 for detection of all 208 
compounds. The compounds were detected at a wavelength of 268 nm. All data were analyzed 209 
by ChemStation software. The phloroglucinol standard was injected at 0.1-100 µg/ml and 210 
phlorotannins in the capsules were analysed as phloroglucinol equivalents. 211 
 212 
RP-HPLC analysis:  The analysis of plasma and urine samples was carried out with a Hewlett-213 
Packard 1100 series liquid chromatograph (Hewlett-Packard, Palo Alto, CA) as previously 214 
described (44). Samples were analyzed by reverse-phase HPLC using a Nova-Pak C18 column 215 
(4.6 x 250 mm) with 4 µm particle size. The temperature of the column was maintained at 30 216 
ºC. The mobile phases consisted of a mixture of aqueous methanol 5 % in 0.1 % hydrochloric 217 
acid 5 M (A) and a mixture of aqueous acetonitrile 50 in 0.1 % hydrochloric acid 5 M (B) and 218 
were pumped through the column at 0.7 ml/min. The following gradient system was used (min 219 
/ % B): 0/5, 5/5, 40/50, 55/100, 59,9/100, 60/5, with 10 min post-run for both compound and 220 
metabolite detections. The eluent was monitored by photodiode array detection at 280 nm and 221 
spectra of products obtained over the 200–600 nm range. Peaks were characterized by their 222 
retention time and spectra characteristics. A calibration curve of phloroglucinol was 223 
constructed using authentic standards (0.1–100 µg/ml) and in each case were found to be linear 224 
with correlation coefficients of 0.995. Metabolites were quantified as phloroglucinol 225 
equivalents.  226 
 227 
LC-MS analysis: LC-MS analysis was conducted to analyse the food grade seaweed capsule, 228 
the urine samples and the digested materials, and was carried out in the negative ion mode 229 
using LC-MS/MS utilizing electrospray ionisation (ESI) as previously described (45).  230 
Characterization was achieved using LC-MS/MS utilizing electrospray ionisation (ESI).  This 231 
consisted of an Agilent 1200 HPLC system equipped with a binary pump, degasser, auto-232 
sampler, thermostat, column heater, photodiode array detector and an Agilent 1100 Series 233 
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LC/MSD Mass Trap Spectrometer.  Separation of samples was achieved using a Zorbax SB 234 
C18 column (2.1 x 100 mm; 1.8 µm) (Agilent) and HPLC conditions were as follows: injection 235 
volume: 1 µL; column temperature: 25 °C; binary mobile system: (A) 0.1 % aqueous formic 236 
acid and (B) 0.1 % of formic acid in acetonitrile; flow rate: 0.2 mL/min.  A series of linear 237 
gradients were used for separation (min/%B): 0/10, 3/10, 15/40, 40/70, 50/70, 65/10. Mass 238 
spectrometry was performed in the negative ion mode (scan range, m/z 100-1000 Da; source 239 
temperature, 350 °C). All solvents used were LC-MS grade. 240 
 241 
Cytokine production:  Blood samples collected during the clinical intervention (baseline, 1 h, 242 
2 h, 4 h, 6 h, 8 h) into heparin tubes, were immediately cultured as follows: 500 μl blood 243 
aliquots were mixed with 500 μl of RPMI media containing antibiotics on a 24 well plate and 244 
LPS (1 μg/ml) or vehicle (control group) were added before incubation at 37 °C for 24 h. At 245 
the end of the culture period, samples were centrifuged at 2000 x g for 5min and the 246 
supernatants were collected and kept at -20 °C until analysis for inflammatory cytokine levels. 247 
The supernatants were collected and stored at -20 °C. Cytokines (IL-1β, IL-6, IL-8, IL-10 and 248 
TNF-α) in the supernatants were measured with Luminex xMAP Technology using 249 
commercially available Fluorokine MAP kits (R&D systems) and data analyzed on the 250 
xPONENT software. Final data are presented as the difference between LPS-treated and un-251 
stimulated control. 252 
 253 
Statistical analysis:  The statistical evaluation of the results was performed by one-way 254 
analysis of variance (ANOVA) followed by a Bonferroni post-hoc t-test using GraphPad InStat 255 
version 5 (GraphPad Software, San Diego, CA, USA). Significant changes are indicated as P 256 
< 0.05. 257 
  258 
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Results  259 
 260 
SPE characterization:  The chromatogram (Figure 1) illustrates the trace obtained by NP-261 
HPLC with diode array detection after injecting a water solution of the SPE. The chromatogram 262 
shows a number of peaks (20-70 min) representing different high molecular weight 263 
phlorotannins, the characteristic phenolics in brown seaweeds. Longer phlorotannin polymers, 264 
which consisted of more hydroxy groups, resulted in tighter attachment to the column material. 265 
Consequently, shorter compounds were released earlier than longer compounds. Owing to a 266 
lack of phlorotannin standards and the complexity of the oligomeric and polymeric forms, the 267 
calibration curve of phloroglucinol was used to quantify all the phlorotannins contained in the 268 
SPE as phloroglucinol equivalents. The SPE comprised a wide range of molecular weight of 269 
phloroglucinol derivatives with a total phlorotannin concentration of 312µg/mg quantified as 270 
phloroglucinol equivalents. Further characterization of the SPE was achieved with LC-MS/MS 271 
(Figure 2) utilizing electrospray ionisation (ESI). The data were collected in a non-targeted 272 
fashion, by acquiring full spectrum data in negative ion mode from m/z 100 to 1000. The data 273 
were then analysed by searching for the theoretical mono-isotopic masses corresponding to 274 
possible phlorotanninoligomers and the presence of ions (1-6) which could correspond to 275 
phlorotannins (Figure 2). The ion 1 with [M-H]- at m/z 405 corresponded to the trimer 276 
hydroxytrifuhalol A, whereas the MS2 fragment -387 corresponded to the loss of one molecule 277 
of water (-18), a characteristic pattern of phlorotannin fragmentation. Compound 2 ([M-H]- at 278 
m/z 497) was considered to be a phlorotannin tetramer composed of 4 phloroglucinol units, 279 
such as tetrafucol or fucodiphlorethol and also in this case the fragment -479 corresponds to 280 
the loss of a molecule of water (-18), whereas the fragment -353 corresponds to the loss of 281 
water (-18) and a phloroglucinol unit (-126), in accordance with analytical profiles recently 282 
described in positive ion mode by Wang et al. (46) and by Ferreres et al. (47). The ion 3 has a 283 
[M-H]- at m/z 247 corresponding to a C-O-C dimer of phloroglucinol as previously indicated 284 
by Nwosu et al (29). The ion 4 (387) corresponds to the trimer 7-hydroxyeckol, and we observe 285 
the presence of a fragment at -369 deriving from the loss of one molecule of water. Isomers 5 286 
and 6 with [M-H]- at m/z 249 were also observed, which can correspond to the dimers 287 
diphlorethol and difucol. 288 
In vitro digestion and characterisation: Due to the lack of commercially available standards 289 
for phlorotannins and the complexity of the oligomers and polymers in the extract, the analysis 290 
of phlorotannins and their metabolites is challenging and requires a combination of approaches.  291 
Similarly to other polyphenol classes, phlorotannins may undergo extensive modification by 292 
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phase I and phase II enzymes and the colonic microbiota during their transit through the 293 
gastrointestinal tract (37),  and the implication of such metabolic modifications on the bioactivity 294 
of phlorotannins has not been investigated yet. Consequently we subjected the SPE to in vitro 295 
digestive and fermentative processes. An in vitro gastric and ileal digestion and colon microbial 296 
fermentation of the SPE was initially conducted, followed by dialysis to simulate absorption 297 
into the circulation. The MS spectra and fragmentations of the compounds detected in the 298 
samples were studied (Figure 3). After in vitro digestion and fermentation procedures, the 299 
samples were analysed by LC-MS/MS utilizing electrospray ionisation (ESI) in negative ion 300 
mode as previously described, searching for the theoretical mono-isotopic masses 301 
corresponding to the low molecular weight phlorotannins previously identified in the capsule 302 
(Figure 2). We were able to identify molecular ions and fragments corresponding to 303 
hydroxytrifuhalol A (405), the C-O-C dimer of phloroglucinol (247), the dimer diphlorethol/ 304 
difucol (249) and 7-hydroxyeckol (387), also found after colonic fermentation. In addition, in 305 
digested and fermented samples subjected to dialysis to mimic absorption into the circulation, 306 
we reported the presence of 7 compounds (DM1 to DM7) corresponding to in vitro absorbed 307 
metabolites.  308 
 309 
Plasma and urine analysis: The food grade SPE was given to healthy subjects (Figure 4) in 310 
the form of a capsule (400 mg) containing 101.89 mg of polyphenols, and blood and urines 311 
were analysed for phlorotannin metabolites. HPLC-DAD analysis of the plasma (Figure 5) and 312 
urine (Figure 6) samples with and without glucuronidase/sulfatase treatment showed the 313 
presence of a variety of metabolites absent in the baselines (before the seaweed capsule 314 
ingestion) in samples from 15 volunteers out of 24. In plasma, the total level of phlorotannins 315 
and their metabolites ranges from 0.011 to 7.757 µg/ml, and in urine from 0.15 to 33.52 are 316 
excreted. Some metabolite peaks were present in samples with and without enzymatic 317 
treatment, and therefore could be assigned to un-conjugated metabolites. Some other 318 
metabolite peaks were present only in samples without enzymatic treatment or were only 319 
appearing in samples enzymatically treated, and were attributed to conjugated forms 320 
(glucuronides and/or sulfates) and their enzymatically released un-conjugated forms. In urine, 321 
some metabolites were found in samples collected at 0-8 h after capsule ingestion, but the 322 
majority of the metabolites were found in samples collected at 8-24 h. Some metabolites, such 323 
as UM6 and UM7, show similar UV spectra characteristics and might therefore be structurally 324 
related (Figure 6). In plasma (Figure 5) some metabolites were found in samples collected at 325 
2, 3 and 4 h after capsule ingestion, but the majority of the metabolites were found in samples 326 
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collected at later time-points (6-24 h).  This could be the result of poor absorption of the high 327 
molecular weight phlorotannins in the upper gastrointestinal tract resulting in them reaching 328 
the colon and undergoing fermentation to lower molecular weight derivatives by the colonic 329 
microbiota. In addition, urine samples were subjected to LC-MS/MS (Figure 7) utilizing 330 
electrospray ionisation (ESI) as previously described, searching for the theoretical mono-331 
isotopic masses corresponding to the low molecular weight phlorotannins previously identified 332 
in the capsule (Figure 2). We were able to identify molecular ions and fragments corresponding 333 
to hydroxytrifuhalol A, 7-hydroxyeckol and the C-O-C dimer of phloroglucinol, which 334 
corresponded to the HPLC metabolite UM3. In addition, we reported the presence of 2 ions 335 
(289 and 377) corresponding to metabolites that we characterized in samples from SPE 336 
subjected to in vitro gastrointestinal digestion and fermentation (DM4 and DM7, figure 3) as 337 
previously detailed. 338 
 339 
Ex-vivo Cytokine production:  340 
The ex-vivo production of cytokines (IL-1β, IL-6, IL-8, IL-10 and TNF-α) relative to baseline 341 
levels in cultured blood collected a various time-points (0, 1, 2, 3, 4, 6 and 8 h) during the 342 
intervention study (LPS treated – unstimulated controls) is reported in Fig 8. The amounts of 343 
TNF-α and IL-10 remained quite stable over time, as well as the amount of all cytokines at 1h 344 
and 2h. IL-6 levels were observed to decrease at later time-points (4 h to 8 h) without reaching 345 
statistical significance (p > 0.05). The levels of both IL-1β and IL-8 were observed to increase 346 
from 3 h to 8 h after the intervention; however the statistical analysis revealed that the only 347 
significant change from baseline levels was the increase of IL-8 at 8 h. 348 




Polyphenols are ubiquitously found in plants and comprise a major part of a daily human diet. 351 
Over the last 20 years, significant data have emerged with regard to the potential beneficial 352 
effects of several classes of phenolic compounds against a number of chronic diseases. In 353 
addition, a reasonable understanding has been gained of the bioavailability of many polyphenol 354 
classes and this will be important for understanding the mechanisms by which they exert such 355 
benefits in vivo. The interest in marine sources of phenolic compounds is recent and knowledge 356 
on phlorotannin bioavailability is still lacking. The analysis of phlorotannins is challenging due 357 
to high range of molecular weight present, and their characterisation is complicated further by 358 
the lack of commercially available standards. 359 
Chromatography techniques coupled to diode array and MS detection have been applied to the 360 
analysis of phlorotannins and the advantages/disadvantages of their use described by Steevensz 361 
et al (34) . Reversed phase High Performance Liquid Chromatography (RP-HPLC) is a 362 
separation mode commonly used for polyphenols separation, however the very high polarity 363 
of phlorotannins would causes them to elute with little or no retention due to the lack of 364 
interaction with the non-polar stationary phase (34; 48). Normal phase liquid chromatography 365 
(NP-HPLC) is more advantageous for retaining compounds with very high polarity, and the 366 
NP-HPLC methodology developed by Koivikko was more suitable than RP-HPLC for the 367 
separation of phlorotannins from the brow algae Fucus vesiculosus (34; 48).  Thus we initially 368 
analysed the phlorotannins in our SPE by Normal-Phase HPLC using a method adapted from 369 
Koivikko et al (8). As expected, the SPE comprised a wide range of molecular weights (20-70 370 
min), with abundance of very high molecular weight phlorotannins eluting at later retention 371 
time (50-70min) in our Normal-Phase method.  MS detection can provide higher sensitivity 372 
and be advantageous to identify specific phlorotannins in the extract without commercially 373 
available standards, however NP-HPLC solvents such as dichloromethane are not suitable for 374 
MS analysis (49), because they would result in poor ionisation and therefore significantly reduce 375 
sensitivity (48; 50). 376 
Nwosu et al. characterized a phlorotannin extract from Ascophyllum nodosum by RP-HPLC 377 
using a C18 column the bound sample eluted in a unresolved set of peaks, and with MS 378 
detection in negative ion mode they were able to assign the detected m/z spectra to a series of 379 
phlorotannin structures (29).  Ferreres et al. identified 22 different phlorotannins belonging to 380 
the eckol and fucophloroethol groups in four seaweed species belonging to the order Fucales 381 
(genus Cystoseira and Fucus) with RP-HPLC separation combined with DAD-ESI-MSn 382 
detection (47).  Using an equivalent RP-HPLC separation method coupled to ESI-MS analysis 383 
14 
 
in negative ion mode we were able to identify some phlorotannin oligomers such as 384 
hydroxytrifuhalol A, tetrafucol, fucodiphlorethol, C-O-C dimmer of phloroglucinol, 7-385 
hydroxyeckol, diphloretol and difucol. The fragmentation patterns of the oligomers we 386 
identified are in agreement with some recent published data in the field (46; 47).  Recently, 387 
Steevensz and his research group characterized the phlorotannins of five brown algae species 388 
by ultrahigh-pressure liquid chromatography operating in “mixed-mode” (hydrophilic 389 
interaction liquid chromatography mode) combined with high resolution mass spectrometry  390 
(34). The methodology proposed by this research group proved to be accurate for profiling 391 
phlorotannins based on their degree of polymerization, and was demonstrated to be an effective 392 
separation mode for low molecular weight phlorotannins, up to 6 KDa (34). 393 
Phlorotannin characterization is a challenging and complex task, complicated by the lack of 394 
commercially available standard compounds, thus chromatography separation coupled to MS 395 
detection can help to elucidate phlorotannin complexity and its application to the analysis of 396 
clinical samples from feeding trials, as well as the use of simplified in vitro digestion systems, 397 
can help elucidate their beneficial health properties and the bioactive circulating forms. The 398 
SPE was subjected to in vitro simulated gastrointestinal digestion and fermentation, followed 399 
by dialysis to simulate as close as possible their absorption and biotransformation. The obtained 400 
materials were analysed by LC-MS for a comparative characterisation of the phlorotannin 401 
metabolites. LC-MA analysis of the digested and fermented SPE have indicated the presence 402 
of some oligomeric phlorotannins also present in the undigested SPE (hydroxytrifuhalol A, 403 
diphloretol/difucol, 7-hydroxyeckol, C-O-Cdimer of phloroglucinol), in addition to a range of 404 
newly formed metabolites (DM1 to DM7). In vitro conditions are indeed a great tool, allowing 405 
a simpler and more convenient analysis, and our in vitro system predicted the formation of 406 
metabolites subsequently identified in urine. 407 
Intervention studies have investigated the fate of polyphenols from land plants in the human 408 
body by measuring plasma concentrations and/or urinary excretion following intake from a 409 
food source.  Many studies performed to investigate polyphenol bioavailability are based on 410 
the measurement of their excretion in urine and plasma by extraction, concentration and 411 
chromatographic separation/analysis, and focused on the detection of polyphenols and their 412 
metabolites in samples subjected or not to enzymatic treatment to release conjugate moieties 413 
such as glucuronic acid and sulphate groups (43; 51). For example, following ingestion of a 414 
polyphenol-rich meal, levels of phenolic compounds and conjugated metabolites can increase 415 
rapidly achieving a peak concentration at approximately 1-2 h in plasma and urine, indicating 416 
small intestinal absorption, or peak at later time-points (4-8 h in plasma, 8-24 h in urine), 417 
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indicating large intestinal metabolism and subsequent absorption (52). In our study, the majority 418 
of phlorotannin metabolites were found in samples collected at late time-points (6-24 h), 419 
indicating limited small intestinal absorption followed by gut microbial metabolism, of the high 420 
molecular weight phlorotannins in the large intestine. 421 
In the upper gastrointestinal tract, dietary polyphenols act as substrates for a number of 422 
enzymes and are subjected to extensive metabolism by glucosidase enzymes, phase I enzymes 423 
(hydrolysing and oxidizing), such as cytochrome P450, and phase II enzymes (conjugating and 424 
detoxifying) found both in the small intestine and the liver (37). In particular there is strong 425 
evidence for the extensive phase II metabolism (by UDP-glucuronosyltransferases, 426 
sulphotransferases) to yield glucuronides and sulphate derivatives. Indeed, there is evidence of 427 
efficient glucuronidation and sulfation of all classes of polyphenols to differing extents (53). 428 
Indeed, our results indicate that phlorotannin intake results in the formation of phase II 429 
conjugate metabolites (glucuronides, sulfates). 430 
Further transformations can occur in the colon, where the enzymes of the gut microbiota act to 431 
breakdown complex polyphenolic structures to smaller units, which may also be absorbed and 432 
further metabolized in the liver.  Bacterial enzymes may catalyse many reactions including 433 
hydrolysis, dehydroxylation, demethylation, ring cleavage and decarboxylation as well as rapid 434 
de-conjugation (54).  435 
As predicted by the high molecular weight range of phlorotannins in our SPE, high colonic 436 
metabolism seems to have occurred, following fermentation of high molecular weight 437 
phlorotannins in the large intestine. By LC-MS analysis, we were able for the first time to 438 
confirm the presence in urine of some phlorotannin oligomers, more specifically 439 
hydroxytrifuhalol A, 7-hydroxyeckol and the C-O-C dimer of phloroglucinol.  Interestingly, 2 440 
of the urine metabolites (m/z 289 and 377) were present in the in vitro digested samples (DM4 441 
and DM7). 442 
There were substantial differences between volunteers in the pattern of phlorotannin 443 
metabolites. Such inter-individual differences have been observed for other polyphenols and 444 
have been attributed to differences in gut microbiota composition and the expression of 445 
metabolizing enzymes (3; 55).  446 
A secondary aim of our work has been to determine whether the SPE could modulate 447 
inflammatory events in the blood, following the absorption of phlorotannin metabolites and 448 
due to their presence into the circulation.  449 
Polyphenols can exert numerous antioxidant and non-antioxidant functions of relevance in 450 
chronic diseases development, and many of them have an important inflammatory component 451 
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(50). In the present study, we observed an altered ex vivo production of IL-8, a low-molecular-452 
weight cytokine produced by mononuclear phagocytes and other cell types, with significant 453 
increased levels of the cytokine after 8h compared to baseline.  454 
IL-8 is an important inflammatory factor of the CXC chemokine family, involved in the 455 
amplification of inflammatory signals (56).  IL-8 secretion is induced by TNF-alfa through a 456 
transcriptional mechanism primarily regulated by nuclear factor-kB (NF-kB) (57). Redox 457 
signalling mechanisms are known to play a role in the regulation of such events, with reactive 458 
oxygen species being able to promote IL-8 production and secretion (18; 23), whereas oxygen 459 
radical scavengers are proven to inhibit IL-8 production in LPS-stimulated human whole blood 460 
(22). Dietary polyphenols such as catechins (33) and curcumin (28) have also been shown to 461 
specifically interfere with IL-8 gene expression through inhibition of NF-kB activation (58). In 462 
consequence, we would have expected circulating seaweed polyphenol metabolites to 463 
potentially be able to inhibit IL-8 secretion. Our results have given a preliminary indication 464 
that the cytokine IL-8 is a possible target for phlorotannin metabolites. However a significant 465 
increase on IL-8 levels at 8h after the intervention was observed, in parallel with the presence 466 
of phlorotannin metabolites in plasma and urine samples. A recent study from our group 467 
investigated the influence of a polyphenol-rich intervention on inflammation as primary 468 
outcome. A randomised, double-blind, placebo-controlled, cross-over acute intervention was 469 
conducted, and cytokine levels (IL-8) were measured with the same ex-vivo experimental 470 
protocol. The results showed a time-dependent increase in IL-8 release compared to baseline, 471 
in accordance with our findings. Thus the post-prandial ex vivo IL-8 production was 472 
significantly attenuated by the intervention compared to the control, with a parallel appearance 473 
in the circulation of polyphenol metabolites. Our trial was a single group interventional study 474 
primarily designed to investigate the bioavailability of seaweed phlorotannins: however, on the 475 
basis of this preliminary indication on their anti-inflammatory potential, not sufficient to draw 476 
any conclusion, a chronic placebo-controlled intervention has been conducted to investigate 477 
the anti-inflammatory effect in deeper detail. 478 
The main limitations of this study arise from the phlorotannin complexity and lack of 479 
commercially available analytical standards, potentially leading to possible quantification 480 
inaccuracy as phloroglucinol equivalents. The lack of analytical standards also implies a 481 
limited capability for method development, especially for the analysis of plasma, urine and 482 
digested materials. In future, the availability of standards could allow a higher degree of 483 
method optimization and the development of specific solid phase ion procedures for sample 484 
clean-up and concentration. 485 
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The development of more recently explored analytical applications to phlorotannins, such as 486 
HILIC (32) and NMR (35) could facilitate the development of more suitable protocols that  487 
could lead to full identification of metabolites and improvements in phlorotannin metabolites 488 
quantification. In addition, The bioacessibility of polyphenols in the form of a capsule/extract 489 
might differ greatly from the bioacessibility of the same compounds in a food matrix (59). Future 490 
work will be needed to determine the potential effects on bioavailability of different food 491 
matrices and also any effects of cooking and/or processing. 492 
Nevertheless, the present work has for the first time started to shed light on the role of colonic 493 
biotransformation on phlorotannin bioavailability, and its implication for their health benefits 494 
in vivo. Our results provide a basis for further investigating the seaweed-derived bioactive 495 
components in the body after ingestion, information which is necessary to understand their 496 
mechanism of action in vivo. 497 
  498 
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List of tables: 499 
Table 1. 500 
Table 1: Key components of polyphenol rich basic extract, High 
Molecular Weight (HMW) fraction, and blend (capsule) showing 
crucial concentrations of polyphenols and iodine.  








Polyphenols 58.74 43.15 101.89 
Iodine  0.46 0.02 0.48 
Maltodextrin*   175 
Minerals 37.77 1.22 38.99 
Fucoxanthin  <0.001 0.004 0.004 
Laminarin as glucose  10.24 1.64 11.88 
Fucoidan as fucose  <0.001 0.23 0.23 
Mannitol  28.03 5.53 33.56 
Inorganic arsenic  <0.001 <0.001 <0.001 
Cadmium (LD 0.15mg/kg) <LD  <LD  <LD  
Mercury (LD 0.016mg.kg) <LD  <LD  <LD  
Lead (LD 1.1mg/kg) <LD  <LD  <LD  
Tin (LD 1.7mg/kg) <LD  <LD  <LD  
*maltodextrin was added to the capsule formulation as an excipient. 
 501 
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FIGURE LEGENDS 530 
 531 
Figure 1. Chromatographic separation of phlorotannins contained in the seaweed extract by 532 
Normal-Phase HPLC with diode array detection (268 nm). 533 
 534 
Figure 2. Characterisation of phlorotannins in the seaweed extract. A: Structures of 535 
phlorotannins identified in the seaweed extract: B: Phlorotannins in the seaweed extracts 536 
identified by LC-MS analysis in negative ion mode 537 
 538 
Figure 3. LC-MS analysis in negative ion mode of the seaweed extract subjected to in vitro 539 
gastrointestinal digestion, colonic fermentation and dialysis to mimic absorption. A: LC-MS 540 
spectra and fragmentation of in vitro digested materials. B: Summary of LC-MS analysis of 541 
the in vitro digested materials 542 
 543 
Figure 4. Schematic illustration of the clinical intervention set up. 544 
 545 
Figure 5. HPLC analysis of plasma samples for seaweed metabolites. A: HPLC 546 
chromatograms (268 nm) and UV spectras showing examples of metabolites in plasma. B: 547 
summary of seaweed metabolites present in plasma samples. 548 
 549 
Figure 6. HPLC analysis of urine samples for seaweed metabolites. A: HPLC chromatograms 550 
(268 nm) and UV spectras showing examples of metabolites in urine. B: summary of seaweed 551 
metabolites present in urine samples. 552 
 553 
Figure 7. LC-MS analysis in negative ion mode of urine samples. A: LC-MS spectra and 554 
fragmentation of phlorotannins found in urine samples. B: Summary of LC-MS analysis of the 555 
urine samples. 556 
 557 
Figure 8. Cytokine production by whole blood cultures in cultured blood collected a various 558 
time-points (0, 1, 2, 3, 4, 6 and 8 h) during the intervention study (LPS treated – unstimulated 559 
controls). a = P < 0.05 vs. baseline. 560 
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